PDF herunterladen
Semin Thromb Hemost 2001; 27(2): 169-174
DOI: 10.1055/s-2001-14077
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Thrombolytic Therapy in Children- Clinical Experiences with Recombinant Tissue-Plasminogen Activator

Ralf Knöfler1 , Jürgen Dinger1 , Maria Kabus1 , Diane Müller1 , Ingrid Lauterbach1 , Edgar Rupprecht2 , Heike Taut-Sack2 , Gerhard Weissbach1
  • 1Department of Pediatrics, Medical Faculty of Technical University Dresden, Dresden, Germany and
  • 2Department of Pediatric Radiology, Medical Faculty of Technical University Dresden, Dresden, Germany
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
31. Dezember 2001 (online)

    Lizenzen und Reprints

ABSTRACT

For the improvement of thrombolytic therapy with recombinant tissue-plasminogen activator (rt-PA) in children, more clinical data are needed. We retrospectively analyzed the clinical course of 20 patients (age ranging from 1 day to 16 years) with venous thrombosis (n = 16), arterial thrombosis (n = 2), and purpura fulminans by meningococcosis (n = 2). The venous thromboses were localized in the iliac-femoral veins (n = 9), brachiocephalic-jugular-subclavian veins (n = 6), and the superior caval vein (n = 1). The arterial occlusions were localized in the abdominal aorta and in the left pulmonary artery. Central venous catheters were of pathogenetic importance in seven cases. The patients were treated with rt-PA for 3 hours to 13 days. The dose ranged between 0.2 and 0.5 mg/kg for the initial bolus and 1.0 to 2.0 mg/kg/d for the continuous infusion. Nineteen patients received simultaneously low-dose unfractionated heparin. Complete clot lysis was detected in 11 cases, a partial lysis in 1, and in 8 patients thrombolytic therapy was not successful. An episode of hematemesis in one patient represented the only serious side effect observed in our study. A systemic decrease in fibrinogen concentration was also rare. In conclusion, thrombolysis with rt-PA represents an effective and safe therapy for children at the dosage used.

KEYWORD

Thrombosis - meningococcosis - thrombolysis - rt-PA - children

REFERENCES

  • 1 Nowak-Göttl U, Auberger K, Halimeh S. Thrombolysis in newborns and infants.  Thromb Haemost . 1999;  112-116 (112-116)
    PubMedGoogle Scholar
  • 2 Chalmers E A, Gibson B ES. Thrombolytic therapy in the management of paediatric thromboembolic disease.  Br J Haematol . 1999;  104 14-21
    CrossrefPubMedGoogle Scholar
  • 3 Collen D, Lijnen H R. Recent developments in thrombolytic therapy.  Fibrinolysis Proteolysis . 2000;  14 66-72
    PubMedGoogle Scholar
  • 4 Leaker M, Massicotte M P, Brooker L A, Andrew M. Thrombolytic therapy in paediatric patients.  Thromb Haemost . 1996;  76 132-134
    PubMedGoogle Scholar
  • 5 Manco-Johnson M J, Nuss R, Hays T. Combined thrombolytic and anticoagulant therapy for venous thrombosis in children.  J Pediatr . 2000;  136 446-453
    CrossrefPubMedGoogle Scholar
  • 6 Wever M LG, Liem K D, Geven W B, Tanke R B. Urokinase therapy in neonates with catheter related central venous thrombosis.  Thromb Haemost . 1995;  73 180-185
    PubMedGoogle Scholar
  • 7 Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry.  Pediatrics . 1995;  96 939-943
    PubMedGoogle Scholar
  • 8 Wermes C, von Depka Prondzinski M, Lichtinghagen R. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters.  Eur J Pediatr . 1999;  S143-S146 (S143-S146)
    PubMedGoogle Scholar
  • 9 Knöfler R, Siegert E, Lauterbach I. Clinical importance of prothrombotic risk factors in pediatric patients with malignancy-impact of central venous lines.  Eur J Pediatr . 1999;  S147-S150 (S147-S150)
    PubMedGoogle Scholar
  • 10 De Mattia D, Penza R, Giordano P. Thromboembolic risk in children with nephrotic syndrome.  Haemostasis . 1991;  21 300-304
    PubMedGoogle Scholar
  • 11 Citak A, Emre S, Sairin A, Bilge I, Nayir A. Hemostatic problems and thromboembolic complications in nephrotic children.  Pediatr Nephrol . 2000;  14 138-142
    CrossrefPubMedGoogle Scholar
  • 12 Zenz W, Bodo Z, Zobel G, Fanconi S, Rettenbacher A. Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans.  Crit Care Med . 1998;  26 969-971
    PubMedGoogle Scholar
  • 13 Veldman A, Ehrenberg A, Jager G. Is recombinant tissue plasminogen activator an option in the treatment of meningococcus-induced purpura?.  Crit Care Med . 2000;  28 598-600
    PubMedGoogle Scholar
  • 14 Nowak-Göttl U, Kreuz W D, Schwabe D, Linde R, Kornhuber B. Thrombolysis with rt-PA in children suffering from arterial or venous thrombosis.  Klin Pädiatr . 1991;  203 359-362
    PubMedGoogle Scholar
  • 15 Dillon P W, Fox P S, Berg C J, Cardella J F, Krummel T M. Recombinant tissue plasminogen activator for neonatal and pediatric vascular thrombolytic therapy.  J Pediatr Surg . 1993;  28 1264-1269
    PubMedGoogle Scholar
  • 16 Anderson B J, Keeley S R, Johnson D. Caval thrombolysis in neonates using low doses of recombinant human tissue-type plasminogen activator.  Anaesth Intensive Care . 1991;  19 22-27
    PubMedGoogle Scholar
  • 17 Varnholt V, Ringe H, Nietsch L, Gaedicke G. Hematothorax under thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) in a 16-year-old girl.  Eur J Pediatr . 1999;  S140-S142 (S140-S142)
    PubMedGoogle Scholar
  • 18 Zenz W, Arlt F, Sodia S, Berghold A. Intracerebral hemorrhage during fibrinolytic therapy in children: a review of the literature of the last thirty years.  Semin Thromb Hemost . 1997;  23 321-332
    Artikel in Thieme ConnectPubMedGoogle Scholar
      >